Shanghai Auzone Biological Technology

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
oxidative stressSmall molecule
Alzheimer's DiseaseAcute Ischemic Stroke

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
October 2028 (1)
Edaravone (TTYP01)Phase 2AD, Early Alzheimer's Disease
Est. primary completion 2028-10-23 · NCT07252440 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 July 2025Filing acceptedEdaravone tablets (TTYP01)NMPA accepts the marketing application for edaravone tablets (TTYP01) in acute ischemic stroke (Huadong Medicine notice 2025-07-31)
CN, NMPA · Shanghai Auzone Biological Technology · Source ↗
30 July 2025Filing acceptedTTYP01NMPA accepts China marketing application for edaravone tablets (TTYP01) in acute ischemic stroke
China, NMPA · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Source ↗

Financial reports

No financial reports recorded.